uploads/2018/08/Chart-02-2-1.jpg

What Analysts Recommend for Haemonetics

By

Updated

Wall Street analysts’ estimates

Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.

The above chart shows analyst recommendations for Haemonetics stock over the last 12 months.

Article continues below advertisement

Analyst ratings

Haemonetics’s stock has increased by nearly 137.2% over the last 12 months and ~66.5% in 2018 year-to-date. Analysts estimate that the stock might fall ~10.2% over the next 12 months. Wall Street analysts have a 12-month target price of $86.86 per share as compared to the last price of $96.71 per share as of August 3.

Analyst recommendations

As of August 3, nine analysts were tracking Haemonetics. Of these nine analysts, two analysts recommend a “strong buy,” two analysts recommend a “buy,” and five analysts recommend a “hold.” There aren’t any “sell” ratings on Haemonetics. The consensus rating for Haemonetics stands at 2.93, which represents a “hold” for value investors.

Haemonetics’s valuation

As of August 3, Haemonetics trades at a forward price-to-earnings multiple of 38.3x as compared to the industry average of 19.9x. Also, the forward EV-to-EBITDA multiple for Haemonetics is 18.9x as compared to the industry average of ~15.3x.

The iShares US Healthcare ETF (IYH) holds 0.1% of its total investments in Haemonetics (HAE), 3.3% in Medtronic (MDT), 2.5% in Thermo Fisher Scientific (TMO), and 9.6% in Johnson & Johnson (JNJ).

Advertisement

More From Market Realist